ADHD Drugmaker Increases Production to Combat Shortage
ADHD Drug Production Increase
The Drug Enforcement Administration (DEA) has announced a 24% increase in the production limit for Takeda Pharmaceutical’s ADHD drug, Vyvanse, and its generic counterparts to tackle ongoing shortages in the United States.
DEA and FDA Collaboration
This adjustment follows a request from the Food and Drug Administration (FDA) made in July. The need for this increase highlights the severe ADHD medication shortages that have persisted for years.
Background on Shortages
- The FDA flagged a shortage of Teva Pharmaceutical's Adderall in October 2022, leading to heightened demand for Vyvanse.
- Vyvanse, known scientifically as lisdexamfetamine, is classified by the DEA as a schedule II controlled substance.
New Production Limits
The recent changes will result in an additional 6,236 kilograms (kg) of lisdexamfetamine being produced to meet the increased domestic and foreign demand. The DEA emphasized that this adjustment is crucial to maintain a steady supply for legitimate patient needs.
Generic Alternatives
Following Takeda's loss of exclusivity, the FDA approved generic versions of Vyvanse from numerous drugmakers, including U.S.-based firms and international producers.
For more details, please visit the source.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.